Wir bieten Ihnen einen Überblick über unsere Publikationen der vergangenen Jahre.

Publikationen 2014

Kahraman D, Theurich S, Rothe A, Kuhnert G, Sasse S, Scheid C, Dietlein M, Drzezga A, von Bergwelt-Baildon M, Kobe C. 18-Fluorodeoxyglucose positron emission tomography / computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin Lymphoma. Leukemia and Lymphoma 2014; 55(4): 811 – 816. IF 2.6

Dietlein F, Eschner W. Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer derived cell lines. Hum Mol Genet 2014 Mar 15; 23(6): 1527 – 1537. IF 6.7

Fanale M, Assouline S, Kuruvilla J, Solal-Céligny P, Heo DS, Verhoef G, Corradini P, Abramson JS, Offner F, Engert A, Dyer MJ, Carreon D, Ewald B, Baeck J, Younes A, Freedman AS. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol 164(2):258-65 (2014) – IF: 5.0

Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, Persigehl T, Klutmann S, Amthauer H, Bockisch A, Kluge R, Wolf HH, Maintz D, Fuchs M, Borchmann P, Diehl V, Drzezga A, Engert A, Dietlein M. The assessment of tumor size reduction improves outcome prediction of PET/CT after chemotherapy in advanced stage Hodgkin lymphoma. J Clin Oncol 2014; IF 17.9

Richter N, Allendorf I, Onur ÖA, Kracht L, Dietlein M, Tittgemeyer M, Neumaier B, Fink GR, Kukolja J. The integrity of the cholinergic system determines memory memory performance in healthy elderly. NeuroImage 2014 IF 6.1

Harms W, Malter W, Krämer S, Drebber U, Drzezga A, Schmidt M. Clinical Significance of Urokinase-type Plasminogen Activator (uPA) and its Type-1 Inhibitor (PAI-1) for Metastatic Sentinel Lymph Node Involvement in Breast Cancer. Anticancer Research 2014; 34 IF: 1.9

Langen KJ, Tonn JC, Weller M, Galldiks N. Letter to the Editor:  “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435-60]. Submitted to J Neurooncol, 2014. IF 2.8

Riedl V, Bienkowska K, Strobel C, Tahmasian M, Grimmer T, Förster S, Friston KJ, Sorg C, Drzezga A. Local activity determines functional connectivity in the resting human brain: a simultaneous FDG-PET/fMRI study J Neurosci. 2014 Apr 30;34(18):6260-6. IF 6.7

Myers N, Pasquini L, Göttler J, Grimmer T, Koch K, Ortner M, Neitzel J, Mühlau M, Förster S, Kurz A, Förstl H, Zimmer C, Wohlschläger AM, Riedl V, Drzezga A, Sorg C. Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer's disease.2014 Jul;137(Pt 7):2052-64. IF 9.3

Ortner M, Kurz A, Alexopoulos P, Auer F, Diehl-Schmid J, Drzezga A, Förster S, Förstl H, Perneczky R, Sorg C, Yousefi BH, Grimmer T.  Small Vessel Disease, but Neither Amyloid Load nor Metabolic Deficit, Is Dependent on Age at Onset in Alzheimer's Disease. Biol Psychiatry. 2014 Jan 31. IF 9.5

Grimmer T, Goldhardt O, Guo LH, Yousefi BH, Förster S, Drzezga A, Sorg C, Alexopoulos P, Förstl H, Kurz A, Perneczky R. LRP-1 polymorphism is associated with global and regional amyloid load in Alzheimer's disease in humans in-vivo.Neuroimage Clin. 2014 Feb 5;4:411-6. IF 1.3

Koch K, Myers NE, Göttler J, Pasquini L, Grimmer T, Förster S, Manoliu A, Neitzel J, Kurz A, Förstl H, Riedl V, Wohlschläger AM, Drzezga A, Sorg C. Disrupted Intrinsic Networks Link Amyloid-β Pathology and Impaired Cognition in Prodromal Alzheimer's Disease.Cereb Cortex. 2014 Jul 4. pii: bhu151. IF 8.3

Klupp E, Förster S, Grimmer T, Tahmasian M, Yakushev I, Sorg C, Yousefi BH, Drzezga A.In Alzheimer's disease, hypometabolism in low-amyloid brain regions may be a functional consequence of pathologies in connected brain regions.Brain Connect. 2014 Jun;4(5):371-83. doi: 10.1089/brain.2013.0212. Kein IF

Alexopoulos P, Kriett L, Haller B, Klupp E, Gray K, Grimmer T, Laskaris N, Förster S, Perneczky R, Kurz A, Drzezga A, Fellgiebel A, Yakushev I; Alzheimer's Disease Neuroimaging Initiative. Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease.Alzheimers Dement. 2014 May 22. pii: S1552-5260(14)00112-5. doi: 10.1016/j.jalz.2014.03.006. IF 17.5

Hitz S, Habekost C, Fürst S, Delso G, Förster S, Ziegler S, Nekolla SG, Souvatzoglou M, Beer AJ, Grimmer T, Eiber M, Schwaiger M, Drzezga A.Systematic Comparison of the Performance of Integrated Whole-Body PET/MR Imaging to Conventional PET/CT for 18F-FDG Brain Imaging in Patients Examined for Suspected Dementia.J Nucl Med. 2014 May 15;55(6):923-931. IF 5.3

Drzezga A, Barthel H, Minoshima S, Sabri O.Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases.J Nucl Med. 2014 May 12;55(Supplement 2):47S-55S. IF 5.3

Drzezga A, Sabri o, Fellgiebel A. Frühdiagnose des Morbus Alzheimer: Amyloid-Bildgebung – Reiffür die Routine?  DeutschesÄrzteblatt 2014, 111(26): A-1206 / B-1042 / C-984 Kein IF

Suleiman AA1, Frechen S, Scheffler M, Zander T, Kahraman D, Kobe C, Wolf J, Nogova L, Fuhr U: Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib IF 5.8

Galldiks N, von Tempelhoff W, Kahraman D, Kracht LW, Vollmar S, Fink GR, Schroeter M, Goldbrunner R, Schmidt M, Maarouf M. 11C-methionine positron emission tomographic imaging of biologic activity of a recurrent glioblastoma treated with stereotaxy-guided laser-induced interstitial thermotherapy. Molecular Imaging 2014 IF 2.2

Sudbrock F, Fischer T, Zimmermanns B, Guliyev M, Dietlein M, Drzezga A, Schomäcker K. Characterisation of SnO2-based 68Ge / 68Ga generators and 68Ga-DOTATATE preparations: Radionuclide purity, radiochemical yield and long-term constancy. Eur J Nucl Med Mol Imaging 2014, submitted IF 5.3

Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrigton SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ. FDG PET/CT: EANM procedure guideline for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2014 IF 5.3

Uhrhan K, Drzezga A, Sudbrock F. The Patient as a radioactive source: An intercomparison of survey meters for measurements in Nuclear Medicine. Radiat Prot Dosim 2014 Jul 27. pii: ncu238

Walberer M, Jantzen SU, Backes H, Rueger MA, Keuters MH, Neumaier B, Hoehn M, Fink GR, Graf R, Schroeter M (2014). In-vivo detection of inflammation and neurodegeneration in the chronic phase after permanent embolic stroke in rats. Brain Res. IF 2.8

Klein R, Blaschke S, Neumaier B, Endepols H, Graf R, Keuters M, Hucklenbroich J, Albrechtsen M, Rees S, Fink GR, Schroeter M, Rueger MA (2014).The synthetic NCAM mimetic peptide FGL mobilizes neural stem cells in vitro and in vivo. Stem Cell Rev. IF 3.2


Kahraman D, Scheffler M, Schmidt M, Neumaier B, Rostamzadeh B, Wolf J, Dietlein M, Drzezga A, Kobe C. PET/CT Diagnostik beim Bronchialkarzinom. Der Nuklearmediziner 2014; 37: 168 – 174. Kein IF

Drzezga A, Sabri O, Fellgiebel A. Frühdiagnose des Morbus Alzheimer: Amyloid-Bildgebung: Reif für die Routine? Deutsches Ärzteblatt 2014; 111: 459 – 462 (Ausgabe M) Kein IF

Dietlein M, Kuhnert G, Semrau R, Nast-Kolb B, Baues C, Fuchs M, Drzezga A, Kobe C. Aktueller Stellenwert der Positronenemissionstomographie beim Hodgkin Lymphom. Der Onkologe 2014, published online IF 0,1

Kreißl MC, Bockisch A, Dietlein M, Grünwald F, Luster M. Inconsistencies. Inhaltliche Inkonsistenzen. Diskussion zu dem Beitrag: Versorgung bei Schilddrüsenknoten – Eine retrospektive Analyse von Krankenkassendaten. Dtsch Arztebl Int 2014 Apr 18; 111(16): 288 doi: 10.3238/arztebl.2014.0288a

Deutsches Ärztebl 2014; 111(16): A288. DOI: 10.3238/aerztebl.2014.0288a (englischsprachige Online-Zeitschrift Deutsches Ärzteblatt International) IF 3.5

Kobe C, Kuhnert G, Kahraman D, Holstein A, Hungenbach S, Engert A, Borchmann P, Fuchs M, Eich H, Kriz H, Baues C, Drzezga A, Dietlein M. PET/CT zur Therapiekontrolle beim Hodgkin Lymphom des Erwachsenen: Hängt die Indikation zur Strahlentherapie vom Ergebnis der PET/CT ab? TumorDiagn u Ther 2014; 35: 97 – 102.  Kein IF

Sudbrock F. Strahlende Arzneimittel? Ionisierende Strahlung in der Medizin Naturwissenschaften im Unterricht - Physik Heft 141 / 142, p. 28 - 31 Kein IF

Publikationen 2013

Bos M, Gardizi M, Schildhaus HU, Heukamp LC, Geist T, Kaminsky B, Zander T, Nogova L, Scheffler M, Dietlein M, Kobe C, Maintz D, Büttner R, Wolf J. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer 2013 Jul; 81(1): 142 – 143. IF 3.7

Furth C, Erdrich AS, Steffen IG, Ruf J, Stiebler M, Kahraman D, Kobe C, Schönberger S, Grandt R, Hundsdoerfer P, Hauptmann K, Amthauer H, Hautzel H. Interim PET response criteria in paediatric non-Hodgkin’s lymphoma. Results from a retrospective multicenter reading. Nuklearmedizin 2013; 52(4): 148 – 156. IF 1.7

Scheffler M, Zander T, Nogova L, Kobe C, Kahraman D, Dietlein M, Papchristou I, Heukamp L, Büttner R, Boellaard R, Lammertsma AA, Querings S, Stoelben E, Engel-Riedel W, Neumaier B, Wolf J. Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptake in patients with lung cancer treated first-line with erlotinib. PloS ONE 2013; Volume 8 Issue 1 e53081, published January 4, 2013. IF 3.5

Meixner M, Hellmich M, Dietlein M, Kobe C, Schicha H, Schmidt M. Disease-free survival in papillary and follicular thyroid carcinoma. Comparison between UICC 5th and 7th classifications of T stage, and the prognostic value of primary tumor size. Nuklearmedizin 2013; 52: 71-80. IF 1.7

Riemann B, Uhrhan K, Dietlein M, Schmidt D, Kuwert T, Dorn R, Sciuk J, Schober O. Diagnostic value and therapeutic impact of 18F-FDG-PET/CT in differentiated thyroid cancer: results of a German multicentre study. Nuklearmedizin 2013; 52: 1-6. IF 1.7

Theurich S, Malcher J, Wennhold K, Shimabukuro-Vornhagen A, Chemnitz J, Holtick U, Krause A, Kobe C, Kahraman D, Engert A, Scheid C, Chakupurakal G, Hallek M, von Bergwelt-Baildon M. Brentuximab Vedotin combined with Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma following Allogenic Stem Cell Transplantation induces Tumor Specific Immunity and Sustained Clinical Remission. J Clin Oncol 2013 Feb 10; 31(5): e59 – 63. IF 17.9

Sasse S, Rothe A, Goergen H, Eichenauer DA, Lohri A, Kreher S, Jäger U, Bangard C, Kuhnert G, Böll B, von Tresckow B, Engert A. Brentuximab vedotin (SGN-35) in patients with transplant-naïve relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2013 Oct; 54(19): 2144-2148. IF 2.6

Behringer K, Müller H, Görgen, H, Thielen I, Eibl A, Stumpf V, Wessels C, Wiehlpütz M, Rosenbrock J, Halbsguth T, Reiners KS, Schober T, Renno JH, von Wolff M, van der Ven K, Kuehr M, Fuchs M, Diehl V, Engert E, Borchmann P on behalf of the German Hodgkin Study Group. Gonadal function and fertility in survivors after Hodgkin Lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol Jan 10;31(2):231-9 (2013)      IF 17.9

Rapic S, Backes H, Viel T, Kummer MP, Monfared P, Neumaier B, Vollmar S, Hoehn M, Van der Linden A, Heneka MT, Jacobs AH. Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013 Jan;34(1):351-4. doi: 10.1016/j.neurobiolaging.2012.04.016. IF 4.9

Chatterjee S, Heukamp LC, Siobal M, Schöttle J, Wieczorek C, Peifer M, Frasca D, Koker M, König K, Meder L, Rauh D, Buettner R, Wolf J, Brekken RA, Neumaier B, Christofori G, Thomas RK, Ullrich RT.Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. 2013 Apr 1;123(4):1732-40. Erratum in: J Clin Invest. 2013 Jul 1;123(7):3183. IF 13.8

Viel T, Boehm-Sturm P, Rapic S, Monfared P, Neumaier B, Hoehn M, Jacobs AH. Non-invasive imaging of glioma vessel size and densities in correlation with tumour cell proliferation by small animal PET and MRI. Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1595-606. doi: 10.1007/s00259-013-2464-1.   IF 4.7

Alexopoulos P, Guo LH, Jiang M, Bujo H, Grimmer T, Förster S, Drzezga A, Kurz A, Perneczky R. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairement with regards to Alzheimer’s disease cerebral metabolic signature. J Alzheimers Dis 2013 Jan 1; 36(2): 401 - 408. IF 3.6

Hungenbach S, Delank KS, Dietlein M, Eysel P, Drzezga A, Schmidt MC. 18F-fluorodeoxyglucose uptake pattern in patients with suspected spondylodiscitis. Nucl Med Commun 2013; 34: 1068 – 1074 IF 1.4

Yakushev I, Chételat G, Fischer FU, Landeau B, Bastin C, Scheurich A, Perrotin A, Bahri MA, Drzezga A, Eustache F, Schreckenberger M, Fellgiebel A, Salmon E. Metabolic and structural connectivity within the default mode network relates to working memory performance in young healthy adults. Neuroimage 2013 Oct 1; 79: 184 - 190. IF 6.1

Tahmasian M, Knight DC, Manoliu A, Schwerthöffer D, Scherr M, Meng C, Shao J, Peters S, Doll A, Khazaie H, Drzezga A, Bäuml J, Zimmer C, Förstl H, Wohlschläger AM, Riedl V, Sorg C. Aberrant intrinsic connectivity of hippocampus and amygdala overlap in the fronto-insular and dorsomedial-prefrontal cortex in major depressive disorders. Front Hum Neurosci 2013 Oct 1 7: 639. IF 2.9

Wagner KJ, Schulz CM, Sprenger T, Pieper T, Heuser F, Hohmann CP, Wermke M, Martin J, Drzezga A. Comparing propofol versus sevoflurane anesthesia for epileptogenic focus detection during positron emission tomography in pediatric patients. Minerva Anestesiol 2013; 79(11): 1264-1268. IF 2.3

Morbelli S, Perneczky R, Drzezga A, Frisoni GB, Caroli A, van Berckel BN, Ossenkoppele R, Guedj E, Didic M, Brugnolo A, Naseri M, Sambuceti G, Pagani M, Nobili F. Metabolic networks underlying cognitive reserve in prodromal Alzheimer disease: a European Alzheimer disease consortium project. J Nucl Med 2013 Jun; 54(6): 894 – 902. IF 5.6

Von Reutern B, Grünecker B, Yousefi BH, Hendriksen G, Czisch M, Drzezga A. Voxel-based analysis of amyloid-burden measured with [11C]PiB PET in a double transgenic mouse model of Alzheimer’s disease. Mol Imaging Biol 2013 Oct; 15(5): 576 – 584. IF 2.9

Dukart J, Perneczky R, Förster S, Barthel H, Diehl-Schmid J, Draganski B, Obrig H, Santarnecchi E, Drzezga A, Fellgiebel A, Frackowiak R, Kurz A, Müller K, Sabri O, Schroeter ML, Yakushev I. Reference cluster normalization improves detection of frontotemporal lobar degeneration by means of FDG-PET. PLoS One. 2013;8(2):e55415. IF 3.5

Plate A, Benninghoff J, Jansen GH, Wlasich E, Eigenbrod S, Drzezga A, Jansen NL, Kretzschmar HA, Bötzel K, Rujescu D, Danek A. Atypical parkinsonism due to a D202N Gerstmann-Sträussler-Scheinker prion protein mutation: first in vivo diagnosed case. Mov Disord. 2013 Feb;28(2):241-4. IF 5.6

Kornberg A, Witt U, Matevossian E, Küpper B, Assfalg V, Drzezga A, Hüser N, Wildgruber M, Friess H. Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC. PLoS One. 2013;8(1):e53960. doi: 10.1371/journal.pone.0053960. Epub 2013 Jan 22. IF 3.5

Galldiks N, von Tempelhoff W, Kahraman D, Kracht LW, Vollmar S, Fink GR, Schroeter M, Goldbrunner R, Schmidt M, Maarouf M. 11C-methionine Positron Emission Tomographic Imaging of Biologic Activity of a Recurrent Glioblastoma Treated with Stereotaxy-Guided Laser-Induced Interstitial Thermotherapy. Mol Imaging 2012; 11: 1 – 7 IF 2.2

Grimmer T, Wutz C, Drzezga A, Förster S, Förstl H, Ortner M, Perneczky R, Kurz A. The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment. Curr Alzheimer Res 2013 Jan; 10(1): 82 – 85. IF 3.8

Catana C, Drzezga A, Heiss WD, Rosen BR. PET/MRI for Neurologic Applications. J Nucl Med. 2012 Dec;53(12):1916-25. IF 5.6

Souvatzoglou M, Eiber M, Takei T, Fürst S, Maurer T, Gaertner F, Geinitz H, Drzezga A, Ziegler S, Nekolla SG, Rummeny EJ, Schwaiger M, Beer AJ, Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2013 Jul 2 IF 5.3

Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, Perani D, Forsberg A, Långström B, Scheinin N, Karrasch M, Någren K, Grimmer T, Miederer I, Edison P, Okello A, Van Laere K, Nelissen N, Vandenbulcke M, Garibotto V, Almkvist O, Kalbe E, Hinz R, Herholz K. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):104-14. IF 5.3

Decarolis B, Roels F, Simon T, Dietlein M, Hero B, Schneider C, Berthold F, Volland R, Schmidt M. I-mIBG scoring allows prediction of outcome in patients with stage 4 neuroblastoma: Results of the Cologne Inter-score Comparison Study. J Clin Oncol 2013; 31 (7): 944 – 951. IF 17.9

Garibotto V, Förster S, Haller S, Vargas M I, Drzezga A, Molecular neuroimaging with PET/MRI. J Clinical and Translational Imaging, February 2013, Volume 1, Issue 1, pp 52-56 Kein IF

Publikationen 2012

Eggers C, Kahraman D, Schmidt M, Timmermann L. Are dopa-responsive dystonia and Parkinson’s disease related disorders? A case report. Parkinsonism Related D 2012; 18: 666-668.
Eggers C, Pedrosa DJ, Kahraman D, Maier F, Lewis CJ, Fink GR, Schmidt M,
Timmermann L. Parkinson subtypes progress differently in clinical course and imaging
pattern. PloS One 2012; Vol 7, Issue 7, e46813.

Engert A, Haverkamp H, Kobe C, Markova J, Lohri A, Ho A, Zijstra J, Král Z, Fuchs M,
Hallek M, Kanz L, Döhner H, Dörken B, Hiddemann W, Einsele HH, Klutmann S,
Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 ;379:1791-1799

Fischer T, Sudbrock F, Pomplun E, Kriehuber R, Winkler J, Matzkies M, Dellweg A,
Dietlein M, Arnhold S, Royer HD, Schicha H, Hescheler J, Schomaecker K. Cellular
response on Auger- and beta-emitting nuclides: human embryonic stem cells (hESC)
vs. keratinocytes. Intern J Radiation Biol (IJRB) 2012; 88. 961-971.

Kahraman D, Keller C, Schneider C, Eschner W, Sudbrock F, Schmidt M, Schicha H,
Dietlein M, Kobe C. Development of hypothyroidism in long-term follow-up in patients
with toxic goiter after radioiodine therapy. Clin Endocrinol 2012; 76(2):297-303.
Kahraman D, Eggers C, Schicha H, Timmermann L, Schmidt M. Visual assessment of
dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with
atypical parkinsonian syndromes and idiopathic Parkinson’s disease. J Neurol 2012;
259: 251-260.

Kahraman D, Eggers C, Holstein A, Schneider C, Pedrosa DJ, Dietlein M, Kobe C,
Timmermann L, Schmidt M. 123I-FP-CIT SPECT imaging of the dopaminergic state:
visual assessment of dopaminergic degeneration patterns reflects quantitative 2D
operator-dependent and 3D operator-independent techniques. Nuklearmedizin 2012;
51: 244-251.

Kahraman D, Holstein A, Scheffler M, Zander T, Nogová L, Lammertsma AA, Boellaard R, Neumaier B, Dietlein M, Wolf J, Kobe C. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clin Nucl Med 2012; 37: 1058-1064.

Kneba, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl
V. Intensity of chemotherapy and PET-guided radiotherapy in patients with advanced
stage Hodgkin lymphoma. Lancet 2012; 379: 1791-1799.

Kobe C, Scheffler M, Holstein A, Zander T, Nogova L, Lammertsma AA, Boellard R,
Neumaier B, Ullrich RT, Dietlein M, Wolf J, Kahraman D. Predictive value of early and
late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging 2012; 39: 1117-1127.

Kriz J, Mueller RP Mueller H, Kuhnert G, Engert A, Kobe C, Haverkamp U, Eich HT.
Large mediastinal tumor mass as a prognostic factor in Hodgkin’s Lymphoma: Is the
definition on the basis of a chest radiography in the era of CT obsolete? Strahlenther
Onkol 2012; 188: 1020-1024.

Markova J, Kahraman D, Kobe C, Skopalova M, Klaskova K, Dedeckova K, Eich H T,
Dietlein M, Kozak T. The role of FDG-PET for early therapy assessment and during
follow-up in patients with advanced Hodgkin lymphoma treated with BEACOPP.
Leukemia Lymphoma 2012; 53(1):64-70

Michels G, Dietlein M, Kobe C, Pfister R. Mediastinal goiter diagnosed without
pathologic examination. Libyan Journal of Medicine 2012; 7.

Müller-Ehmsen J, Tossios P, Schmidt M, Scheid C, Ünal N, Bovenschulte H,
Hackenbroch M, Krug B, Goßmann A, Mehlhorn U, Schwinger RHG, Erdmann E.
Transmurality of scar influences the effect of a hybrid-intervention with autologous bone marrow cell injection and aortocoronary bypass surgery (MNC/CABG) in patients after myocardial infarction. Int J Cardiol 2012; 156: 303-308.

Scheffler M, Kobe C, Zander T, Nogova L, Kahraman D, Thomas R, Neumaier B,
Dietlein M, Wolf J. Monitoring reversible and irreversible EGFR inhibition with erlotinib
and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using
sequential [18F]fluorothymidine (FLT-)PET. Lung Cancer 2012; 77: 617-620.
Schmidt M, Uhrhan K, Markiefka B, Hasselbring L, Schlaak M, Cremer B, Kunze S,
Baum RP, Dietlein M. 68Ga-DotaTATE PET-CT followed by peptide receptor
radiotherapy in combination with capecitabine in two patients with Merkel cell
carcinoma. Int J Clin Exp Med 2012; 5(4): 363-366.

Schneider C, Schlaak M, Bludau M, Markiefka B, Schmidt M. 68Ga-DOTATATE-PET/CT
positive metastatic lymph node in a 69-year-old woman with Merkel Cell Carcinoma.
Clin Nucl Med 2012, 37(11): 1108-1111.

Schneider C, Simon T, Hero B, Schulze-Uphoff U, Drebber U, Alakus H, Holinski-Feder
E, Berthold F, Dietlein M, Schmidt M. [18F]fuorodeoxyglucose positron emission
tomograph/computed tomography-positive gastic adenocarcinoma in a 12-year-old girl with Peutz-Jeghers syndrome. J Clin Oncol 2012, 30: e140-143.

Schneider C, Dietlein M, Eschner W, Schmidt M, Kahraman D, Kobe C. Recombinant
human TSH increases uptake and effective half-life of radioiodine in thyroid hormone
secreting metastases of follicular thyroid cancer. Exp Clin Endocrinol Diabetes 2012;
120: 160-163.

Schneider C. Kahraman D, Kobe C. Differentiated thyroid carcinoma – is there any
evidence for the use of recombinant human TSH in thyroid hormone secreting
metastasis? [Letter] J Nucl Med 2012; 53: 1329-1330.
Schneider C, Kobe C, Schmidt M, Kahraman D, Malchau G, Faust M, Schicha H,
Dietlein M. Calcitonin screening in nodular thyroid disease. Nuklearmedizin 2012; 51:

Schulte D, Faust M, Schmidt M, Ruge M, Grau S, Blau T, Kocher M, Krone W, Laudes
M. Novel therapeutic approaches to CNS metastases in malignant pheochromocytomas – case report of the first patient with a large cystic CNS lesion. Clin Endocrinol 2012; 77: 332-334.
Verburg FA, Dietlein M, Freudenberg L, Leboulleux S, Pitoia F, Reiners C, Stokkel M, Luster M. Recombinant human TSH vs. Thyroid hormone withdrawal [letter]. J Nucl Med 2012; 53(11): 1815-1816.

Publikationen 2011

Furth C, Hundsdoerfer P, Ruf J, Schiefer J, Schönberger S, Dietlein M, Amthauer H, Grandt R, Hautzel H, Henze G, Kobe C. Evaluation of interim PET for response assessment in pediatric Hodgkin lymphoma – results for dedicated assessment criteria in a blinded, dual center read. Ann Oncol 2011; 22: 1198 – 1203.

Eggers C, Kahraman D, Fink G, Schmidt M, Timmermann L. Akinetic-rigid and tremor-dominant Parkinson’s disease patients show different patterns of FP-CIT SPECT. Movement Disord 2011; 26 (3): 416 – 423.

Dietlein M, Verburg A, Luster M, Reiners C, Schicha H. One should not just read what one believes – the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer [editorial]. Eur J Nucl Med Mol Imaging 2011; 38: 793 - 798.

Zander T, Scheffler M, Nogová L, Kobe C, Papachristou I, Engel-Riedel W, Toepelt K, Hellmich M, Heukamp L, Buettner R, Ko YD, Ullrich R, Smit E, Boellaard R, Lammertsma AA, Jacobs A, Schlesinger A, Schulte K, Querings S, Stoelben E, Neumaier B, Thomas R, Dietlein M, Wolf J. Early prediction of disease control in advanced non-small cell lung cancer treated with erlotinib using 18F-fluorothymidin and 18F-fluorodeoxyglucose positron emission tomography. J Clin
Oncol 2011; 29 (13):1701-8

Kahraman D, Goretzki PE, Szangolies M, Schade H, Schmidt M, Kobe C. Extra-adrenal
pheochromocytoma in the organ of Zuckerkandl: Diagnosis and treatment strategies. Exp Clin Endocrinol Diabetes 2011; 119: 436 – 439.

Brisse HJ, McCarville MB, Granata C, Krug B, Wootton-Gorges S, Kanegawa K, Giammarile F, Schmidt M, Shulkin BL, Matthay KK, Lewington VJ, Sarnacki S, Hero B, Kaneko M, London WB, Pearson ADJ, Cohn SL, Monclair T. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011; 261: 243 – 257.

Schmidt M, Kahraman D, Neumaier B, Ortmann M, Stippel D. Tc-99m-MIBI-negative
parathyroid adenoma in primary hyperparathyroidism detected by C-11-methionine PET-CT after previous thyroid surgery. Clin Nucl Med 2011; 36(12):1153-5.

Kahraman D, Scheffler M, Zander T, Nogová L, Lammertsma A, Boellaard R, Neumaier B, Holstein A, Dietlein M, Wolf J, Kobe C. Quantitative analysis of response to treatment with Erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3’-Deoxy-3’-18Ffluorothymidine PET. J Nucl Med 2011; 52(12):1871-7.

Schomäcker K, Sudbrock F, Fischer T, Dietlein M, Kobe C, Gaidouk M, Schicha H. Exhalation of 131I after radioiodine therapy: measurement in exhaled air. Eur J Nucl Med Mol Imaging 2011; 38: 2165 - 2172.

Eschner W, Kobe C, Schicha H. Follow-up on thyroidal uptake after radioiodine therapy – how robust is the peri-therapeutic dosimetry?. Z Med Phys (Zeitschrift für Medizinische Physik) 2011; 21(4): 258-265.

Hammes J, Pietrzyk U, Schmidt M, Schicha H, Eschner W. GATE based Monte Carlo simulation of planar scintigraphy to estimate the nodular dose in radioiodine therapy for autonomous thyroid adenoma. Z Med Phys (Zeitschrift für Medizinische Physik) 2011; 21(4): 290-300.

Sudbrock F. Dose and dose rate measurements for radiation exposure scenarios in nuclear medicine. Radiation Measurements 2011; 46: 1303 - 1306.

Wilkens H, Lang I, Behr J, Berghaus T, Grohe C, Guth S, Hoeper MM, Kramm T, Krüger U, Langer F, Rosenkranz S, Schäfers HJ, Schmidt M, Seyfarth HJ, Wahlers T, Worth H, Mayer E. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated recommendations of the Cologne Consensus Conference 2011. Intern J Cardiol 2011; 154 (Suppl. 1): S54 – S60. (December 2011)

Sudbrock F. Praktischer Strahlenschutz im Krankenhaus: Ein Blick in die Nuklearmedizin der Uniklinik Köln. Strahlenschutzpraxis 2011, Heft 1: 41-49.

Luster M, Dietlein M. Therapie gutartiger Schilddrüsenerkrankungen. Wann Medikamente, wann Radiojod, wann Operation? Ars Medici 2011; Heft 19: 775-778.

Publikationen 2010

Eschner W, Schmidt M, Dietlein M, Schicha H. PROLARA: prognosis-based lifetime
attributable risk approximation for cancer from diagnostic radiation exposure. Eur J Nucl Med Mol Imaging 2010; 37(1): 131 - 135.

Düren C, Dietlein M, Luster M, Plenzig F, Steinke R, Grimm J, Groth P, Reiners C. The
use of thyrogen in the treatment of differentiated thyroid carcinoma: an intraindividual comparison of clinical effects and economic aspects. Exp Clin Endocrinol Diabetes 2010; 118: 513-519.

Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, Dietlein M, Schicha H.
Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I ? Nucl Med Commun 2010; 31: 201-205.

Kotzerke J, Dietlein M, Grünwald F, Bockisch A. Vorbehalte der DGN zur
Nutzenbewertung der PET durch das IQWiG. Nuklearmedizin 2010; 49(1): 6 - 12.

Kobe C, Dietlein M, Fuchs M. Interim positron emission tomography scan in Hodgkin
lymphoma: definitions, interpretation rules, and clinical validation [letter]. Leukemia
Lymphma 2010; 51(3): 552 - 553.

Breustedt B, Eschner W. Monte Carlo calibration of whole-body counters with NaI(Tl)
detectors in Stretcher geometry. Radiat Prot Dosimetry 2010; 139(4): 510 – 518.

Dietlein M, Börner SM, Fischer T, Hansen H, Schnell R, Zimmermanns B, Tawadros S,
Eschner W, Engert A, Staak JO, Pogge von Strandmann E, Kobe C, Schicha H,
Schomäcker K. Development of an iodine-131-labeled murine anti-CD30 monoclonal
antibody (131I-Ki-4): in vitro studies with L540 Hodgkin cell lines, animal studies and a feasibility study for radioimmunotherapy in patients with refractory Hodgkin’s lymphoma. Nuklearmedizin 2010; 49(3): 97 - 105.

Vallboehmer D, Hoelscher AH, Schneider PM, Schmidt M, Dietlein M, Bollschweiler E,
Baldus S, Alakus H, Brabender J, Metzger R, Moenig SP. [18F]-fluorodeoxyglucosepositron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol 2010; 102: 135-150

Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H. Dosimetry for 131IMIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2010; 37: 1279 – 1290.

Alakus H, Batur M, Schmidt M, Drebber U, Baldus SE, Vallböhmer D, Prenzel KL,
Metzger R, Bollschweiler E, Hölscher AH, Mönig SP. Variable 18F-fluorordeoxyglucose
uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl
Med Commun 2010; 31: 532 – 538.

Riemann B, Krämer JA, Schmid KW, Dralle H, Dietlein M, Schicha H, Sauerland C,
Frankewitsch T, Schober O. Risk stratification of patients with locally aggressive
differentiated thyroid cancer: results of the MSDS trial. Nuklearmedizin 2010; 49: 79 -84.

Krämer JA, Schmid KW, Dralle H, Dietlein M, Schicha H, Lerch H, Gerss J,
Frankewitsch T, Schober O, Riemann B. Primary tumour size is a prognostic parameter in patients suffering from differentiated thyroid carcinoma with extrathyroidal growth: results of the MDS trial. Eur J Endocrinol 2010; 163(4): 637 – 644.

Gassanov G, Dietlein M, Caglayan E, Erdmann E, Er F. Amiodaron-induzierte
Schilddrüsenfunktionsst.rungen. Dtsch Med Wochenschr. 2010; 135: 807 – 811.

Dietlein M, Eich HT, Fuchs M, Borchmann P, Engert A, Kobe C. PET beim Hodgkin-
Lymphom – Verbessert die Positronenemissionstomographie die Behandlung? Der
Onkologe 2010; 16: 18-27.

Dietlein M, Luster M, Reiners C. Nuklearmedizinische Therapie und Nachsorge des
differenzierten Schilddrüsenkarzinoms: Status quo. Der Onkologe 2010; 16(7): 678-689.

Stokkel MPM, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM
procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging 2010; 37: 2218 - 2228.

Lorenz R, Dietlein M, Reiners C. Stationäre nuklearmedizinische Therapie in
Deutschland– Analyse der strukturierten Qualitätsberichte 2004 bis 2008.
Nuklearmedizin 2010; 49: 49 – 57.

Dafotakis M, Schmidt M, Meister IG, Fink GR, Dennin A, Nowak DA. Degenerative
anterior biopercular syndrome initially misdiagnosed as a psychogenic disorder. J
Neurology 2010; 257: 1576 – 1578.

Vogt H, Schmidt M, Bares R, Brenner W, Grünwald F, Kopp J, Reiners C, Schober O,
Schümichen C, Schicha H, Sciuk J, Sudbrock F, Wengenmair H. Procedure guideline
for sentinel lymph node diagnosis. [Verfahrensanweisung für die nuklearmedizinische
Wächter-Lymphknoten (sentinel lymph node; SLN)- Diagnostik. Nuklearmedizin 2010;49: 167-172.

Kobe C, Dietlein M, Kriz J, Furth C, Fuchs M, Borchmann P, Engert A, Eich HT. The
role of PET in Hodgkin lymphoma and its impact on radiation oncology. Expert Rev
Anticancer Ther 2010; 10(9): 1419-1428.

Dietlein M, Busemeyer S, Kobe C, Schmidt M, Theissen P, Schicha H. Costminimization-analysis for recombinant human TSH versus hypothyroidism in the followup care of differentiated thyroid cancer. Nuklearmedizin 2010; 49: 216 – 224.

Schmidt M, Bollschweiler E, Hölscher A. F-18-Fluorodeoxyglucose positron emission
tomography for the evaluation of neoadjuvant therapy response in esophageal cancer. (Letter) Ann Surg 2010; 252: 412-413.

Schmidt M, Baum RP, Simon T, Howman-Giles R. Therapeutic nuclear medicine in
pediatric malignancy. Q J Nucl Med Mol Imaging 2010; 54: 411-428.

Wilkens H, Lang I, Behr J, Berghaus T, Grohe C, Guth S, Hoeper MM, Kramm T,
Krüger U, Langer F, Schäfers HJ, Schmidt M, Seyfarth HJ, Wahlers T, Worth H, Mayer
E. Chronische thromboembolische pulmonale Hypertonie. Empfehlungen der Kölner
Konsensus-Konferenz 2010. Dtsch Med Wochenschr 2010; 135: S125 – S130.

Nia AM, Gassanov N, Schmidt M, Kuhn-Régnier F, Erdmann E, Er F. Rare cause for
sudden right heart failure. The Scientific World Journal 2010; 10: 1996 – 1998 (DOI

Dietlein M, Luster M, Reiners C. Differenziertes Schilddrüsenkarzinom: risikoadaptierte Behandlung und Nachsorge – Update 2010. Thieme-Refresher Onkologie 2010; 3(1): R1 – R24.

Dietlein M, Kobe C, Luster M. Differenziertes Schilddrüsenkarzinom: Fortschritte bei der Radioiod-Ablation. Der Nuklearmediziner 2010; 33(4):203 – 213.

Schmidt M, Schicha H. MIBI-SPECT bei kalten Knoten zur
Schilddrüsenkarzinomdetektion. Der Nuklearmediziner 2010; 33(4): 214 – 221.

Dietlein M, Kobe C, Neumaier B, Ullrich R. Nichtkleinzelliges Bronchialkarzinom:
Molekulare Bildgebung mittels PET und translationale Forschung. onkopipeline 2010;
3(2): 99 - 105.

Kobe C, Dietlein M. Die Positronenemissionstomografie in den Hodgkin-Lymphom-
Studien der GHSG. Krebsmedizin 2010; 19(3): 117 - 122.

Zimmermanns B, Fischer T, Schomäcker K. Qualitätskontrolle von Radiopharmaka –
Gesetzliche Grundlagen (1). MTA Dialog 2010; 11(2): 112 – 114.

Zimmermanns B, Fischer T, Schomäcker K. Qualitätskontrolle von Radiopharmaka –
Qualitätskriterien (2). MTA Dialog 2010; 11(3): 188 – 191.

Zimmermanns B, Fischer T, Schomäcker K. Qualitätskontrolle von Radiopharmaka –
Kontrolle der radiochemischen Reinheit (3). MTA Dialog 2010; 11(4): 282 – 285.

Luster M, Dietlein M. Therapie gutartiger Schilddrüsenerkrankungen – Wann
Medikamente, wann Radioiod, wann Op.? Der Allgemeinarzt 2010, Heft 13: 3-10.

Publikationen 2009

Schmidt M, Bollschweiler E, Dietlein M, Mönig SP, Kobe C, Vallboehmer D, Eschner W,
Hölscher A, Schicha H. Mean and maximum standardized uptake values in [18F] FDGPET for assessment of histopathological response in oesophageal squamous cell
carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging
2009; 36: 735-740.

Markova J, Kobe C, Skopalova M, Klaskova K, Dedeckova K, Plütschow A, Eich HT,
Dietlein M, Engert A, Kozak T. FDG-PET for assessment of early treatment response
after 4 cycles of chemotherapy in patients with advanced-stage Hodgkin lymphoma has a high negative predictive value. Ann Oncol 2009; 20: 1270-1274.

Verburg FA, Dietlein M, Lassmann M, Luster M, Reiners C. Why radioiodine remnant
ablation is right for most patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009; 36: 343-346.

Sudbrock F, Boldt F, Kobe C, Hammes J, Eschner W, Schicha H. Radiation exposure in
the environment of patients after application of radiopharmaceuticals. Part 2:
Therapeutic procedures. Nuklearmedizin 2009; 48: 17-25.

Furth C, Steffen IG, Amthauer H, Ruf J, Misch D, Schönberger S, Kobe C, Denecke T,
Stöver B, Hautzel H, Henze G, Hundsdoerfer P. Early and late therapy response
assessment with FDG-PET in pediatric Hodgkin lymphoma: an analysis of a prospective multicenter trial. J Clin Oncol 2009; 27(26): 4385 - 4391.

Nogová L, Boellaard R, Kobe C, Hoetjes N, Zander T, Gross SH, Dimitrijevic S, Pellas
T, Eschner W, Schmidt K, Bangard C, Hayes W, Thomas RK, Dietlein M, Giaccone G,
Hoekstra OS, Lammertsma AA, Wolf J. Downregulation of 18F-FDG uptake in PET as
an early pharmacodynamic effect in treatment of non-small cell lung cancer with the
mTOR inhibitor everolimus. J Nucl Med 2009; 50(11): 1815 - 1819.

Bachmann J, Kobe C, Bor S, Rahlff I, Dietlein M, Schicha H, Schmidt M. Radioiodine
therapy for thyroid volume reduction of large goitres. Nucl Med Commun 2009; 30: 466-471.

Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus S, Mönig S, Metzger R, Schicha H, Schmidt M. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surgery 2009; 250: 888-894.

Theissen P, Schmidt M, Ivanova T, Dietlein M, Schicha H. MIBI scintigraphy in
hypofunctioning thyroid nodules. Can it predict the dignity of the lesion? Nuklearmedizin 2009; 48: 144-152.

Schicha H, Hellmich M, Lehmacher W, Eschner W, Schmidt M, Kobe C, Schober O,
Dietlein M. Should all patients with thyroid nodules Ñ 1 cm undergo fine-needle
aspiration biopsy? Nuklearmedizin 2009; 48: 79-83.

Albus C, Theissen P, Hellmich M, Griebenow R, Wilhelm B, Aslim D, Schicha H, Köhle
K. Long-term effects of a multimodal behavioral intervention on myocardial perfusion – a randomized controlled trial. Int J Behav Med 2009; 16(3): 219-226.

Klehr M, Koehl U, Mühlenhoff M, Tawadros S, Fischer T, Schomäcker K, Heuckmann
JM, Bochennek K, Jensen M. The novel chimeric anti-NCAM (Neural Cell Adhesion
Molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not
activate complement-dependent cytolysis (CDC). J Immunother 2009; 32: 442-451.

Publikationen 2008

Wüllner U, Gündisch D, Herzog H, Minnerop M, Joe A, Warnecke M, Jessen F, Schütz
C, Reinhardt M, Eschner W, Klockgether T, Schmaljohann J. Smoking upregulates
alpha4beta2 nicotinic acetylcholine receptors in the human brain. Neurosci Lett /
Neuroscience Letter 2008 ; 430 : 34-37.

Dietlein M, Wegscheider K, Vaupel R, Schmidt MC, Schicha H. Survey of management
of solitary thyroid nodules in Germany. Nuklearmedizin 2008; 47: 87-96.

Dietlein M, Wieler H, Schmidt M, Schwab R, Goretzki PE, Schicha H. Routine
measurement of serum calcitonin in patients with nodular thyroid disorders? [German]. Nuklearmedizin 2008; 47: 65-72.

Schmidt M, Thoma N, Dietlein M, Moka D, Eschner W, Faust M, Pollock M, Schröder
W, von Hülst-Schlabrendorff M, Ehses W, Schicha H. 99mTc-MIBI SPECT in primary
hyperparathyroidism. Influence of concomitant vitamin D deficiency for visualization of parathyroid. Nuklearmedizin 2008; 47: 1 - 7.

Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, Schicha H. Graves’
disease and radioiodine therapy: is success of ablation dependent on the absorbed
dose above 200 Gy? Nuklearmedizin 2008; 47: 13 - 17.

Kobe C, Weber I, Eschner W, Sudbrock F, Schmidt M, Dietlein M, Schicha H. Graves’
disease and radioiodine therapy: is success of ablation dependent on the choice of
thyreostatic medication? Nuklearmedizin 2008; 47: 153 - 166.

Schnell R, Dietlein M, Schomäcker K, Kobe C, Borchmann P, Schicha H, Hallek M,
Engert A. Yttrium-90 ibritumimab tiuxetan induced complete remission in a patient with classical lymphocyte-rich Hodgkin lymphoma. Onkologie 2008; 31: 49-51.

Dietlein M, Bell E, Gemmer P, Göller T, Goretzki PE, Jacob R, Keuser R, Musholt TJ,
Daid S, Schicha H, Schwab R, Wilbert H, Wieler H. Calcitonin-Screening bei der
Knotenstruma? Ärzteblatt Rheinland-Pfalz 2008; Ausgabe 3/März 2008.

Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, Klutmann S, Knapp W, Zijlstra JM, Bockisch A, Weckesser M, Lorenz R, Schreckenberger M, Bares R, Eich
HT, Mueller RP, Fuchs M, Borchmann P, Gossmann A, Schicha H, Diehl V, Engert A.
Positron emission tomography has a high negative predictive value for progression or
early relapse for patients with residual disease after first line chemotherapy in
advanced-stage Hodgkin Lymphoma. Blood 2008; 112: 3989-3994.

Sobottke R, Seifert H, Fätkenheuer G, Schmidt M, Goßmann A, Eysel P. Aktuelle
Diagnostik und Therapie der Spondylodiszitis. Dtsch Arztebl 2008; 105(10): 181-187.

Schmidt M, Simon T, Hero B, Schicha H, Berthold F: The prognostic impact of
functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma > 1 year of age on a high-risk treatment protocol. Results of the German Neuroblastoma trial NB97. Eur J Cancer 2008; 44: 1552-1558.

Pfister R, Diedrichs H, Dietlein M, Erdmann E, Schneider CA. Typical and atypical
takotsubo-like cardiomyopathy as a manifestation of pheochromocytoma. [letter] J
Endocrinol Invest 2008; 31: 382-383.

Franzius C, Schmidt M, Hero B, Pfluger T, Hahn K. Procedure guidelines for MIBGscintigraphy in children. Nuklearmedizin 2008; 47: 132-138.

Dietlein M, Kahaly G, Kobe C, Schmidt M, Derwahl K-M, Schicha H. Adipositas,
Stoffwechsel und Schilddrüse: Ist der grenzwertig hohe TSH-Spiegel Ursache oder
Sekundärphänomen der Adipositas? Nuklearmedizin 2008; 47: 181-187.

Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen W, Tennvall J, Bombardieri E. Guidelines for radioiodine treatment of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008; 35: 1941-1959.

Schmidt M, Voell M, Rahlff I, Dietlein M, Kobe C, Faust M, Schicha H. Long-term followup of antithyroid peroxidase antbodies in patients with chronic autoimmune thyroiditis (Hashimoto’s thyroiditis) treated with levothyroxine. Thyroid 2008; 18: 755-760.

Tossios P, Krausgrill B, Schmidt M, Fischer T, Halbach M, Fries JWU, Fahnenstich S,
Frommolt P, Heppelmann I, Schmidt A, Schomäcker K, Fischer JH, Bloch W, Mehlhorn
U,, Schwinger RHG, Müller-Ehmsen J. Role of balloon occlusion for mononuclear bone
marrow cell deposition after intracoronary injection in pigs with reperfused myocardial infarction. Eur Heart J 2008; 29: 1911-1921.

Schröder U, Dietlein M, Wittekindt C, Ortmann M, Stuetzer H, Vent J, Jungehuelsing M, Krug B. Is there a need for PET imaging to stage the N0 neck in T1-T2 squamous cell carcinoma of the oral cavity and oropharynx? Annals Otology Rhinology Laryngology 2008; 117(11): 854-863.

Reiners C, Dietlein M, Luster M. Radioiodine therapy in differentiated thyroid cancer:
indications and procedures. Best Practice & Research Clinical Endocrinology &
Metabolism 2008; 22(6): 989 - 1007

Kobe C, Dietlein M, Mauz-Körholz C, Engert A, Borchmann P, Sabri O, Schober O,
Schicha H, Kluge R. FDG-PET in Hodgkin lymphoma. Nuklearmedizin 2008; 47: 235-

Reiners C, Dietlein M, Luster M. Struma maligna – Schilddrüsenkarzinome. Dtsch Med
Wochenschr 2008; 133: 2215-2228.

Schicha H, Eschner W, Fischer T, Dietlein M, Schmidt M, Schomäcker K. Derzeitiger
Stand und Entwicklungstendenzen in der Nuklearmedizin. Nova Acta Leopoldina 2008; 96(355): 133 – 141.

Kobe C, Kracht LW, Timmermann L, Bachmann J, Schmidt M. Perrault syndrome with
progressive nervous system involvement. Clin Nucl Med 2008; 33: 922-924.
Schmidt M, Huff W, Dietlein M, Kobe C, Schicha H. Interactions between brain, psyche and thyroid. Nuklearmedizin 2008; 47: 225-234.

Sudbrock F, Boldt F, Kobe C, Eschner W, Schicha H. Radiation exposure in the
environment of patients after application of radiopharmaceuticals. Part 1: Diagnostic
procedures. Nuklearmedizin 2008; 47: 267-274.

Fischer T, Schomäcker K, Schicha H. Diethylstilbestrol (DES) labeled with Auger
emitters: Potential radiopharmaceutical for therapy of estrogen receptor-positive tumors and their metastases? Int J Radiat Biol 2008; 84: 1112-22.

Publikationen 2007

Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD. Use of Positron Emission Tomography (PET) for Response Assessment of Lymphoma: Consensus Recommendations of the Imaging Subcommittee of the International Harmonization Project (IHP) in Lymphoma. J Clin Oncol 2007; 25(2): 571-578.

Dietlein M, Moka D, Reinholz U, Schmidt M, Schomäcker K, Schicha H, Wellner U. Who might benefit from administration of additional inactive iodine during radioiodine therapy for Graves’ disease ? Nuklearmedizin 2007, 41 (3): 77-87.

Dietlein M, Wegscheider K, Vaupel R, Schmidt MC, Schicha H. Management of
multinodular goiter in Germany. Do the approaches of thyroid specialists and primary
care practitioners differ? (Papillon 2005) Nuklearmedizin 2007; 41 (3): 65-75.

Dietlein M, Wegscheider K, Vaupel R, Schmidt MC. Ärztebefragung zur Versorgung bei
diffuser Struma: Kombinationstherapie hat die Nase vorn. Der Hausarzt 2007; Heft 7:

Schmidt M, Delank K-S, Dietlein M, Schicha H. Nuklearmedizinische Abklärung bei
vermuteter Infektion einer Hüft- oder Knie-TEP. Der Nuklearmediziner 2007; 30: 140-153.

Kahaly G, Dietlein M, Gärtner R, Mann K, Dralle H. Amiodaron und
Schilddrüsendysfunktion. Dtsch Ärzteblatt 2007; 104(51-52): C 3021 – C 3026.

Dietlein M, Dressler J, Escher W, Grünwald F, Lassmann M, Leisner B, Luster M, Moser E, Reiners C, Schicha H, Schober O. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). [German]. Nuklearmedizin 2007; 46: 213-219.

Dietlein M, Dressler J, Eschner W, Grünwald F, Lassmann M, Leisner B, Luster M,
Reiners C, Schicha H, Schober O. Procedure guideline for iodine-131 whole-body
scintigraphy for differentiated thyroid cancer (version 3). Nuklearmedizin 2007; 46: 206-212.

Dietlein M, Dressler J, Grünwald F, Leisner B, Moser E, Reiners C, Schicha H,
Schneider P, Schober O. Guideline for radioiodine therapy for benign thyroid diseases
(version 4). [German] Nuklearmedizin 2007; 46: 220-223.

Dietlein M, Dressler J, Eschner W, Leisner B, Reiners C, Schicha H. Procedure
guideline for thyroid scintigraphy (version 3). [German] Nuklearmedizin 2007; 46: 203-205.

Dietlein M, Dressler J, Eschner W, Lassmann M, Leisner B, Reiners C, Schicha H.
Procedure guideline for radioiodine test (version 3). [German] Nuklearmedizin 2007; 46: 198-202.

Franzius C, Dietlein M, Biermann M, Frühwald M, Linden T, Bucsky P, Reiners C,
Schober O. Procedure guideline for radioiodine therapy and 131Iodine whole-body
scintigraphy in paediatric patients with differentiated thyroid cancer. [German]
Nuklearmedizin 2007; 46: 224-231.

Dietlein M, Schober O, Schicha H. Radioiodtherapie und 131I-Ganzkörperszintigraphie
zwischen evidentia und evidence. Anmerkungen zur Aktualisierung der
Verfahrensanweisungen und Leitlinien. Nuklearmedizin 2007; 46: 155-160.

Jensen M, Klehr M, Vogel A, Schmitz S, Tawadros S, Mühlenhoff M, Plück A, Fischer T,
Schomäcker K, Schultze JL, Berthold F. One step generation of fully chimeric antibodies using Cgamma1- and Ckappa transgenic mice. J Immunother 2007; 30: 338-349.

Kobe C, Schmidt M, Kracht L, Dietlein M, Schicha H. PET in der Onkologie: Nutzen und Chancen. best practice onkologie 2007; 2(3): 22-32.

Bachmann J, Ernestus K, Werner T, Garnier Y, Mallmann P, Pietsch C, Schicha H,
Schmidt M. Detection of primary choriocarcinoma in the mediastinum by F-18 FDG
positron emission tomography. Clin Nucl Med 2007; 32: 663-665.

Eschner W. Strahlenschutz bei der nuklearmedizinischen Bildgebung.
Strahlenschutzpraxis 2007; 13(4): 16-21.

Publikationen 2006

Dederichs B, Dietlein M, Jenniches-Kloth B, Schmidt M, Theissen P, Schicha H.
Radioiodine therapy of Graves’ hyperthyroidism in patients without pre-existing
ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy? Exp Clin Endocrinol Diabetes 2006; 366-370.

Delank KS, Schmidt M, Michael JWP, Dietlein M, Schicha H, Eysel P. The implications
of 18F-FDG-PET for the diagnosis of endoprosthetic loosening and infection in hip and
knee arthroplasty. BMC Musculoskeletal Disorders 2006; 7: 20 – 29.

Dietlein M, Dederichs B, Kobe C, Theissen P, Schmidt M, Schicha H. Therapiekonzepte
der euthyreoten Struma nodosa – Die Radioiodtherapie bietet eine attraktive Alternative zur Operation. Nuklearmedizin 2006; 45(1): 21-34.

Guntinas-Lichius O, Klussmann JP, Dinh S, Dinh M, Schmidt M, Semrau R, Mueller RP.
Diagnostic work-up and outcome of cervical metastases from an unknown primary. Acta Oto-Laryngol 2006; 126: 536–544.

Marx K, Moka D, Schomäcker K, Fischer T, Dietlein M, Gabruck-Szostak B, Schicha
H. Cell death induced by radioiodine therapy in differentiated thyroid carcinoma:
Necrosis or apoptosis? Nucl Med Commun 2006; 27: 353-358.

Mernagh P, Campell S, Dietlein M, Luster M, Mazzaferri E, Weston AR. Costeffectiveness of using recombinant human TSH (rhTSH) prior to radioiodine therapy ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006; 155: 405-414.

Mix M, Eschner W. Bildrekonstruktion und Quantifizierung in der
Emissionstomographie. Z Med Phys 2006; 16(1): 19-30.

Otto C, Jensen M, Dietlein M, Fischer T, Zimmermanns B, Schmidt M, Tawadros S,
Börner SM, Weber SA, Spitz R, Berthold F, Schicha H, Schomäcker K. Localization of
131I-labeled monoclonal antibody ERIC1 in a subcutaneous xenograft model of
neuroblastoma in SCID mice. Nucl Med Commun 2006; 27: 171-178.

Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H. Is there a benefit of 131I-MIBG therapy in the treatment of children with stage 4 neuroblastoma. Nuklearmedizin 2006; 45: 145-151.

Schmidt M, Schneider C, Theissen P, Erdmann E, Schicha H. QT dispersion in
comparison to Tl-201-SPECT for detection of myocardial ischaemia. Int J Cardiol 2006; 113: 327-331.

Schmidt M, Gorbauch E, Dietlein M, Faust M, Stützer H, Eschner W, Theissen P,
Schicha H. Incidence of post-radioiodine immunogenic hyperthyroidism / Graves’
disease in relation to a temporary increase in TSH-receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid 2006; 16(3): 281-288.

Schmidt M, Dietlein M, Schröder U, Schicha H. False-positive uptake of I-131 in a
laryngocele mimicking thyroid remnant after thyroidectomy for papillary thyroid
carcinoma. Clin Nucl Med 2006; 31: 716-717.

Simon T, Hero B, Bongartz R, Schmidt M, Müller RP, Berthold F. Intensified externalbeam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual disease. Strahlenther Onkol 2006; 182: 389-394.
Sudbrock F, Eschner W, Schmidt M, Schicha H, Simon T, Hero B. Dosimetrie bei der
Therapie von Neuroblastomen mit 131I-mIBG. Nuklearmedizin 2006; 40: 254-261.

Tossios P, Müller-Ehmsen J, Schmidt M, Scheid C, Ünal N, Moka D, Schwinger RHG,
Mehlhorn U. No evidence of myocardial restoration following transplantation of
mononuclear bone marrow cells in coronary bypass grafting surgery patients based
upon cardiac SPECT and 18F-PET. BMC Medical Imaging 2006; 6: 7 (published online).

Bamberg M, Diehl V, Herrmann T, Juergens H, Siewert JR, Bartenstein P, Baum RP,
Dietlein M, Geworski L, Haberkorn U, Kluge R, Knapp WH, Kotzerke J, Kuwert T,
Nitzsche E, Reske SN, Reuland P, Schicha H, Schober O, Schwaiger M, Stabell U, van
den Hoff J. Positron emission tomography (PET) in oncology: a part of medical
therapeutic expertise. Dtsch Med Wochenschr 2006; 131 (10): 512-515.

Schleimer K, Stippel DL, Kaspar HU, Tawadros S, Suer C, Schomäcker K, Hölscher A,
Beckurts KT. Auxiliary liver transplantation with flow-regulated portal vein arterialisation offers a successful therapeutic option in acute hepatic failure – investigations in heterotopic auxiliary rat liver transplantation. Transpl Int 2006; 19(7): 581-588.

Tossios P, Müller-Ehmsen J, Schmidt M, Scheid C, Ünaf N, Moka D, Schwinger RHG,
Mehlhorn U. No evidence of myocardial restoration following transplantation of
mononuclear bone marrow cells in coronary bypass grafting surgery patients based
upon cardiac SPECT and 18F-PET. Heart Views 2006; 7(3): 88-96.

Publikationen 2005

Albus C, Theissen P, Hellmich M, Griebenow R, Wilhelm B, Aslim D, Schicha H, Köhle
K. Long-term effects of ambulant, multimodal intervention on myocardial perfusion and cardiac occurrence in patients with coronary cardiacdisease – a randomised controlled study. Psychother Psychosom Med Psychol 2005; 55(2): 91.

Biermann M, Pixberg MK, Dörr U, Dietlein M, Schlemmer H, Grimm J, Zajic T, Nestle U, Ladner S, Sepehr-Rezai S, Rosenbaum S, Puskás C, Fostitsch P, Heinecke A, Schuck A, Willich N, Schmid KW, Dralle H, Schober O. Impact of clinical practice guidelines on radioiodine therapy for differentiated thyroid carcinoma. Nuklearmedizin 2005; 44: 229-237.

Diedrichs H, Zobel C, Theissen P, Weber M, Koulousakis A, Schicha H, Schwinger RH.
Systematic relief precedes improvement of myocardial blood flow in patients under
spinal cord stimulation. Curr Control Trials Cardiovasc Med 2005; 6(1):7.

Dietlein M, Schicha H. Amiodarone-induced thyrotoxicosis due to destructive thyroiditis. Therapeutic considerations. Exp Clin Endcrinol Diabetes 2005; 113: 145-151.

Dietlein M, Luyken WA, Schicha H, Larena-Avellaneda A. Incidental multifocal papillary microcarcinomas of the thyroid: Is subtotal thyroidectomy combined with radioiodine ablation enough? Nucl Med Commun 2005; 26: 3-8.

Dietlein M, Pels H, Schulz H, Borchmann P, Schomäcker K, Fischer T, Eschner W,
Schicha H, Engert A, Schnell R. Imaging of CNS lymphomas with iodine-123 labeled
rituximab. Eur J Haematol 2005; 74: 348-352.

Dietlein M, Kobe C, Schmidt M, Schicha H. Das Inzidentalom der Schilddrüse. Über oder Unterdiagnostik eines epidemiologischen Befundes? Nuklearmedizin 2005; 44:

Grönke S, Schmidt M, Schwinger RHG. Typische Angina-pectoris-Beschwerden ohne
koronare Makroangiopathie. Dtsch Med Wochenschr 2005, 130: 942-945.

Kersting UG, Stubendorff JJ, Schmidt MC, Brüggemann G-P. Changes in knee cartilage volume and serum COMP concentration after running exercise. OsteoArthritis and Cartilage 2005; 13: 925-934.

Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients
with differentiated thyroid carcinoma: a 130-patient pilot survey on consequences of
hypothyroidism and pharmacoeconomic comparison with recombinant thyrotropin
administration. Thyroid 2005; 15: 1147-1155.

Schmidt M, Eschner W, Dietlein M, Theissen P, Schicha H. Konventionelle
nuklearmedizinische Tumordiagnostik (Tumor-SPECT): Was ist angesichts von 18FFDG-PET noch aktuell? Nuklearmedizin 2005; 44: 37-48.

Schnell R*, Dietlein M*, Staak JO, Borchmann P, Schomäcker K, Fischer T, Eschner W, Hansen H, Morschhauser F, Schicha H, Diehl V, Raubitschek A, Engert A. Treatment of refractory Hodgkin lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody (131I-Ki-4). J Clin Oncol 2005; 23: 4669-4678. [*Both authors contributed equally to this work.]

Schomäcker K, Dietlein M, Schnell R, Pinkert J, Eschner W, Zimmermanns B, Fischer
T, Engert A, Schicha H. Radioimmuntherapie mit 90Y-markiertem Ibritumomab-Tiuxetan: Klinik, Radiopharmazie, Strahlenschutz, Perspektiven. Nuklearmedizin 2005; 44: 166-177.

Schomäcker K, Dietlein M, Mödder G, Boddenberg-Pätzold B, Zimmermanns B, Fischer T, Schicha H. Stability of radioactive colloids for radiation synovectomy: influence of xray contrast agents, anesthetics and glucocorticoids in vitro. Nucl Med Commun 2005; 26: 1027-1035.

Theissen P, Schneider PM, Dietlein M, Hölscher AH, Schicha H. Wertigkeit der
Positronenemissionstomographie für das Staging beim Ösophaguskarzinom.
Viszeralchirurgie 2005; 40: 242-245.

Theissen P, Schneider PM, Baldus SE, Jost A, Dietlein M, Müller RP, Hölscher AH,
Schicha H. Monitoring of tumor response to neoadjuvant radio-chemotherapy of
esophageal carcinoma by F-18-FDG-PET. Chinese German J Clin Oncol 2004; 3: 257-

Publikationen 2004

Breustedt B, Paetz H, Schicha H, Eschner W. [Calibration of a whole body counter
using Monte Carlo methods.] Z Med Phys 2004; 14(2): 85-94.

Dietlein M, Dressler J, Farahati J, Grünwald F, Leisner B, Moser E, Reiners C, Schicha
H, Schober O. Verfahrensanweisung zur Radioiodtherapie (RIT) beim differenzierten
Schilddrüsenkarzinom (Version 2). Nuklearmedizin 2004; 43: 115-120.

Dietlein M, Dressler J, Grünwald F, Leisner B, Moser E, Reiners C, Schicha H,
Schneider P, Schober O. Leitlinie zur Radioiodtherapie bei benignen
Schilddrüsenerkrankungen (Version 3). Nuklearmedizin 2004; 43: 217-220.

Dietlein M, Schober O, Schicha H. Über- oder Untertherapie des papillären
Mikrokarzinoms der Schilddrüse? Überlegungen zur ablativen Radioiodtherapie.
Nuklearmedizin 2004; 43: 107-114.

Fischer T, Schomäcker K, Schicha H. Labelling, purification, and receptor affinity of
radioactive iododiethylstilbestrol (I-DES) with high specific activity and first structure
analysis with natI-DES. J Label Comp Radiopharm 2004; 47: 669-678.

Reiners C., Wegscheider K., Schicha H., Theissen P., Vaupel R., Wrbitzky R.,
Schumm-Draeger PM. Prevalence of thyroid disorders in the working population of
Germany: ultrasonography screening in 96,278 unselected employees, Thyroid 2004;
14(11): 926-932.

Schicha H, Reiners C, Moser E, Schober O. Subclinical thyroid disease. Nuklearmedizin 2004; 43: 69-71.

Schmidt M, Schmalenbach M, Jungehülsing M, Theissen P, Dietlein M, Schröder U,
Eschner W, Stennert E, Schicha H. 18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of
qualitative visual and semiquantitative analysis. Nuklearmedizin 2004; 43: 91–101.

Schmidt M, Voth E, Schneider CA, Theissen P, Wagner R, Baer FM, Schicha H. F-18-
FDG uptake is a reliable predictory of functional recovery of akinetic but viable infarct
regions as defined by magnetic resonance imaging before and after revascularization.
Magn Reson Imaging 2004; 22: 229 – 236.

Publikationen 2003

Diedrichs H, Weber M, Voth E, Koulousakis A, Zobel C, Schwinger RH. [Increased
myocardial blood flow after spinal cord stimulation in patients with refractory angina
pectoris]. Med Klin (Munich) 2003; 98(3): 146-150.

Dietlein M, Dressler J, Eschner W, Lassmann M, Leisner B, Reiners C, Schicha H.
Verfahrensanweisung zum Radioiodtest (Version 2). Nuklearmedizin 2003; 42 : 116-

Dietlein M, Dressler J, Eschner W, Leisner B, Reiners C, Schicha H. Verfahrensanweisung für die Schilddrüsenszintigraphie (Version 2). Nuklearmedizin
2003; 42 : 120-122.

Dietlein M, Dressler J, Eschner W, Leisner B, Reiners C, Schicha H.
Verfahrensanweisung für die Iod-131-Ganzkörperszintigraphie beim differenzierten
Schilddrüsenkarzinom (Version 2). Nuklearmedizin 2003; 42 : 123-125.

Dietlein M, Dressler J, Grünwald F, Joseph K, Leisner B, Moser E, Reiners C, Rendl J,
Schicha H, Schober O. Leitlinien zur Schilddrüsendiagnostik (Version 2) Nuklearmedizin 2003; 42: 109-115.

Dietlein M, Moka D, Schmidt M, Theissen P, Schicha H: Prävention, Screening und
Therapie gutartiger Schilddrüsenerkrankungen unter dem Aspekt von Kosten und
Nutzen. Nuklearmedizin 2003; 42: 181-189.

Dietlein M, Schicha H. Lifetime follow-up care is necessary for all patients with treated thyroid nodules [letter]. Eur J Endocrinol 2003; 148: 377-379.

Dietlein M, Schicha H. Vergütung der PET in der Onkologie in Europa: Eine Umfrage.
Nuklearmedizin 2003; 42: 80-85.

Dietlein M, Weber W, Schwaiger M, Schicha H. 18F-Fluorodeoxyglukose-
Positronenemissionstomographie in der Rezidivdiagnostik des kolorektalen Karzinoms: evidenzbasierte Empfehlungen und Kosten/Nutzenabwägungen. Nuklearmedizin 2003; 42: 145-156.

Hummel T, Damm M, Vent J, Schmidt M, Theissen P, Larsson M, Klussmann JP: Depth
of olfactory sulcus and olfactory function. Brain Research 2003; 975: 85–89.

Kappert K, LaRosée K, Karasch T, Kuhn-Regnier F, Schmidt M, Rosenkranz S:
Dünnwandiges Herzspitzenaneurysma bei hypertropher obstruktiver Kardiomyopathie. Dtsch Med Wochenschr 2003; 128: 1342–1346.

Staak JO, Dietlein M, Engert A, Weihrauch MR, Schomäcker K, Fischer T, Eschner W,
Borchmann P, Diehl V, Schicha H, Schnell R. Hodgkin’s lymphoma in nuclear medicine: diagnostic and therapeutic aspects. Nuklearmedizin 2003; 42: 19-24.

Walter C, Scheidhauer K, Scharl A, Göring UJ, Theissen P, Kugel H, Krahe T, Pietrzyk
U. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in
suspicious breast lesions. Eur Radiol 2003; 13(7): 1651-1656.

Weber W, Dietlein M, Hellwig D, Kirsch C-M, Schicha H, Schwaiger M. PET mit 18FFluorodeoxyglukose in der Diagnostik des nicht-kleinzelligen Bronchialkarzinoms:
evidenzbasierte Empfehlungen und Kosten/Nutzenabwägungen. Nuklearmedizin 2003; 42: 135-144.

Weihrauch MR, Dietlein M, Schicha H, Diehl V, Tesch H. Prognostic significance of 18Ffluorodeoxyglucose positron emission tomography in lymphoma. Leuk Lymphoma 2003; 44: 15-22. 

Publikationen 2002

Bäumer AT, Nickenig G, Moka D, Bohm M: [Coronary-subclavian steal syndrome].
Dtsch Med Wochenschr 2002; 127(21): 1134-6.

Becker W, Schicha H. The thyroid. Eur J Nucl Med Mol Imaging 2002; 29(Suppl 2):

Damm M, Vent J, Schmidt M, Theissen P, Eckel HE, Lötsch J, Hummel T: Intranasal
volume and olfactory function. Chemical Senses 2002; 27: 831 – 839.

Dietlein M, Schicha H. PET in der nuklearmedizinischen Diagnostik – Kosten/Nutzen-
Aspekte. Nuklearmedizin 2002; 41: 202-207.

Dose J, Kotzerke J, Schicha H, Rieber A, Schelling M, Paulsen F, Avril N.
Recommendations of the 3rd interdisciplinary German consensus conference PET in
oncology III. Geburtshilfe Frauenheilkd 2002; 62(7): 644-651.

Herholz K, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidhauer K, Schicha H,
Heiss WD, Ebmeier K. Direct comparison of spatially normalized PET and SPECT
scans in Alzheimer’s disease. J Nucl Med 2002; 43(1): 21-26.

Kahaly GJ, Dietlein M. Cost estimation of thyroid disorders in Germany. Thyroid 2002;
12: 909-914.

Kreuzberg U, Schmidt M, Metzger R, Schirmacher P, Kämmerer F, Schütt-Gerowitt H,
Schicha H: Zervikale Tuberkulose einer Ductus-thyreoglossus-Zyste. Nuklearmedizin
2002; 41: 87–89.

Leyendeckers H, Voth E, Schicha H, Hunzelmann N, Banga P, Schmitz J. Frequent
detection of thyroid peroxidase-specific IgG+ memory B cells in blood of patients with
autoimmune thyroid disease. Eur J Immunol 2002; 32(11): 3126-3132.

Moka D, Dietlein M, Schicha H: Radioiodine therapy and thyrostatic drugs and iodine.
Eur J Nucl Med Mol Imaging 2002; 29(Suppl 2): S486-S491.

Moka D, Dietlein M, Raffelt K, Hahn J, Schicha H. Differentiation between healthy
thyroid remnants and tumor tissue after radioiodine therapy in patients with
differentiated thyroid carcinoma using in-vitro phosphorus-31 magnetic resonance
spectroscopy. Am J Med 2002; 112(8): 634-641.

Schaefer WM, Moka D, Brockmann HA, Schomaecker K, Schicha H: 201Tl, 99mTc-
MIBI, 99mTc-tetrofosmin and 99mTc-furifosmin: relative retention and clearance
kinetics in retrogradely perfused guinea pig hearts. Nucl Med Biol 2002; 29(2): 243-54.

Scheidhauer K, Odatzidu L, Kiencke P, Schicha H. [Body weight gain after radioiodine
therapy in hyperthyroidism]. Nuklearmedizin 2002; 41(1): 47-51.

Schicha H, Dietlein M. Morbus Basedow und Autonomie – Radioiodtherapie.
Nuklearmedizin 2002; 41: 63-70.

Schmidt M, Fischer E, Dietlein M, Michel O, Weber K, Moka D, Stennert E, Schicha H.
Clinical value of somatostatin receptor imaging in patients with suspected head and
neck paragangliomas. Eur J Nucl Med Mol Imaging 2002; 29(12): 1571-1580.

Schmidt M, Jockenhövel F, Theissen P, Dietlein M, Krone W, Schicha H. [Assessment
of endocrine disorders of the hypothalamic-pituitary axis by nuclear medicine
techniques]. Nuklearmedizin 2002; 41(4): 80-90.

Süllentrop F, Moka D, Neubauer S, Haupt G, Engelmann U, Hahn J, Schicha H. 31P
NMR spectroscopy of blood plasma: determination and quantification of phospholipid
classes in patients with renal cell carcinoma. NMR Biomed 2002; 15(1): 60-8.

Weihrauch MR, Re D, Bischoff S, Scheidhauer K, Dietlein M, Ansen S, Franklin J,
Bohlen H, Wolf J, Schicha H, Diehl V, Tesch H. Whole-body positron emission
tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann Hematology 2002; 81: 20-25.

Publikationen 2001

Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H,
Bredow J, Körber C, Grünwald F. Fluorine-18 fluorodeoxyglucose positron emission
tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001; 28: 1671–1676.

Dietlein M, Moka D, Weber K, Theissen P, Schicha H. Cost-effectiveness of PET for the
management of lung tumours: comparison of economic data. Nuklearmedizin 2001; 40: 122–128.

Ebel H, Schomäcker K, Balogh A, Volz M, Funke J, Schicha H, Klug N. High cervical
spinal cord stimulation (CSCS) increases regional cerebral blood flow after induced
subarachnoid hemorrhage in rats. Minim Invasive Neurosurg 2001; 44(3): 167-171.

Ebel H, Semmelmann G, Friese M, Volz M, Lee JY, Dück M, Schomäcker K, Varga J,
Furka I, Schröder R, Klug N. Effects of electrical stimulation of the Gasserian ganglion
on regional cerebral blood flow after induced subarachnoid hemorrhage in pigs
evaluated by 99mTc-HMPAO-SPECT. Minim Invasive Neurosurg 2001; 44(1): 50-57.

Füssl R, Baer FM, Schwinger RH, La Rosee K, Diederichs H, Dederichs B, Höpp HW.
[Angiographically unexplained myocardial ischemia in high grade coronary stenosis with main stem involvement in intravascular ultrasound.] Dtsch Med Wochenschr 2001; 126(10): 286-272.

Geoerger B, Hero B, Harms D, Grebe J, Scheidhauer K, Berthold F. Metabolic activity
and clinical features of primary ganglioneuromas. Cancer 2001; 91(10): 1905-1913.
Kim WY, Danias PG, Stuber M, Flamm SD, Plein S, Nagel E, Langerak SE, Weber OM,
Pedersen EM, Schmidt M, Botnar RM, Manning WJ. Coronary magnetic resonance
angiography for the detection of coronary stenosis. N Engl J Med 2001; 345(26): 1863-1869.

Moka D, Baer FM, Theissen P, Schneider CA, Dietlein M, Erdmann E, Schicha H. Non-
Q-wave myocardial infarction: impaired myocardial energy metabolism in regions with reduced 99mTc-MIBI accumulation. Eur J Nucl Med 2001; 28: 602-607.

Rosenkranz S, Voth E, LaRosée K, Baer FM, Kettering K, Smolarz K, Moka D, Schicha
H, Erdmann E, Deutsch H. Identification of hemodynamically significant restenosis after percutaneous transluminal coronary angioplasty in acute myocardial infarction by transesophageal dobutamine stress echocardiography and comparison with myocardial Single Photon Emission Computed Tomography. J Interven Cardiol 2001; 14: 271–282.

Schmidt M, Theissen P, Moka D, Voth E, Schmitter HT, Schicha H. Tc-99m MIBI
SPECT correlated with magnetic resonance imaging for cardiac evaluation of a patient
with congenitally corrected transposition of the great arteries (L-TGA). Clin Nucl Med
2001; 26(8): 714-5.

Schmidt M, Jochims M, Theissen P, Baer FM, Crnac J, Voth E, Schneider CA, Erdmann
E, Schicha H. [Comparison of dobutamine-stress magnetic resonance imaging and
dipyridamole-Tl-201-SPECT as alternative strategies for the detection of coronary artery disease in patients no suitable for stress echocardiography]. Nuklearmedizin 2001; 40(6): 198-206.

Schomäcker K, Fischer T, Eschner W, Gaidouk MI, Schicha H: [Exhalation of 131I after radioiodine therapy: time dependence and chemical form]. Nuklearmedizin 2001; 40: 15-22.

Simon T, Voth E, Berthold F. Asymmetric salivary gland 123I-meta-iodobenzylguanidine uptake in a patient with cervical neuroblastoma and Horner syndrome. Med Pediatr Oncol 2001; 36(4): 489-490.

Urbannek V, Voth E, Moka D, Schicha H. [Radioiodine therapy of Graves' disease--a
dosimetric comparison of various therapy regimens of antithyroid agents].
Nuklearmedizin 2001; 40(4): 111-115.

Weber K, Wellner U, Voth E, Schicha H. [Influence of stable iodine on the uptake of the thyroid – model versus experiment.] Nuklearmedizin 2001; 40(1): 31-37.

Weihrauch MR, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, Bohlen H, Wolf
J, Schicha H, Diehl V, Tesch H. Thoracic positron emission tomography using 18Ffluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930–2934. 

Publikationen 2000

Baer FM, Theissen P, Crnac J, Schmidt M, Deutsch HJ, Sechtem U, Schicha H,
Erdmann E. Head to head comparison of dobutamine-transoesophageal
echocardiography and dobutamine-magnetic resonance imaging for the prediction of left ventricular functional recovery in patients with chronic coronary artery disease. Eur Heart J 2000; 21(12): 981-991.

Baer FM, Crnac J, Schmidt M, Jochims M, Theissen P, Schneider C, Schicha H,
Erdmann E. Magnetic resonance pharmacological stress for detecting coronary
disease. Herz 2000; 25(4): 400-8.

Börner AR, Voth E, Theissen P, Wienhard K, Wagner R, Schicha H. Glucose
metabolism of the thyroid in autonomous goiter measured by F-18-FDG-PET. Exp Clin
Endocrinol Diabetes 2000; 108: 191-196.

Büll U, Bartenstein P, Kirsch CM, Schicha H. [Combined systems for SPECT,
Coincidence, PET and CT - Technical spectrum, operation requirements and possible
applications]. Nuklearmedizin 2000; 39(1): 3A-6A.

Dietlein M, Moka D, Scheidhauer K, Schmidt M, Theissen P, Voth E, Eschner W,
Schicha H. Follow-up care of differentiated thyroid cancer: Comparison of multiple
diagnostic tests. Nucl Med Commun 2000; 21: 991-1000.

Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, Schicha H.
Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a
decision analysis based on cost reimbursement in Germany. Eur J Nucl Med 2000; 27 : 1441-1456.

Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, Schicha H.
Cost-effectiveness of FDG-PET for the management of potentially operable non-small
cell lung cancer (NSCLC): priority for a PET-based strategy after nodal-negative CT
results. Eur J Nucl Med 2000; 27: 1598-1609.

Eschner W, Vogg R, Braunlich I, Mack C, Wagner R, Schicha H. Incorporation risks for
workers in PET centers. Radiat Prot Dosimetry 2000; 89 (3-4): 211-213.
Hussy E, Voth E, Schicha H. [Sonographic determination of thyroid volume –
comparison with surgical data]. Nuklearmedizin 2000; 39(4): 102-107.

Jungehülsing M, Scheidhauer K, Damm M, Pietrzyk U, Eckel H, Schicha H, Stennert E.
2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000 123(1): 294-301.

Kreuzberg U, Theissen P, Schicha H, Schröder F, Mehlhorn U, de Vivie ER, Boknik P,
Neumann J, Grohe C, Herzig S. Single-channel activity and expression of atrial L-type
Ca(2+) channels in patients with latent hyperthyroidism. Am J Physiol Heart Circ Physiol2000; 278(3): 723-730.

Krug B, Dietlein M, Groth W, Stützer H, Psaras T, Gossmann A, Scheidhauer K,
Schicha H, Lackner K. Fluor-18-fluorodeoxyglucose positron emission tomography
(FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging
methods. Acta Radiol 2000: 41: 446-452.

Malja S, Schomäcker K, Malja E. Preparation of Y-90 by the Sr-90-Y-90 generator for
medical purpose. J Radioanal Nucl Chem 2000; 245(2): 403-406.
Moka D, Voth E, Dietlein M, Larena-Avellaneda A, Schicha H. Preoperative localization
of parathyroid adenomas using 99mTc-MIBI scintigraphy. Am J Med 2000; 108(9): 733–736.

Moka D, Voth E, Dietlein M, Larena-Avellaneda A, Schicha H. 99mTc-MIBI-SPECT in
preoperative diagnostics of primary hyperparathyroidism. Surgery 2000; 128(1): 29-35.

Moka D, Eschner W, Voth E, Dietlein M, Larena-Avellaneda A, Schicha H. Iterative
reconstruction: an improvement of technetium–99m MIBI SPET for the detection of
parathyroid adenomas? Eur J Nucl Med 2000; 27(5): 485–489.

Raffelt K, Moka D, Süllentrop F, Dietlein M, Hahn J, Schicha H. Systemic alterations in
phospholipid concentrations of blood plasma in patients with thyroid carcinoma: an invitro 31P high resolution NMR study. NMR Biomed 2000; 13 : 8–13.

Schmidt M, Theissen P, Deutsch HJ. Double-outlet right ventricle after operative
correction. Clin Cardiol 2000; 23(6): 459.

Schmidt M, Theissen P, Klempt G, Deutsch HJ, Baer FM, Dietlein M, Moka D, Erdmann
E, Schicha H. Long-term follow-up of 82 patients with chronic disease of the thoracic
aorta using spin-echo and cine gradient magnetic resonance imaging. Magn Reson
Imaging 2000; 18(7): 795-806.

Schmidt M, Theissen P, Deutsch HJ, Dederichs B, Franzen D, Erdmann E, Schicha H.
Congenitally corrected transposition of the great arteries (L-TGA) with situs inversus
totalis in adulthood; findings with magnetic resonance imaging. Magn Reson Imaging
2000 18(4): 417-422.

Schmidt M, Scheidhauer K, Urbannek V, Luyken C, Friese M, Voth E, Schicha H.
[Metastasizing follicular thyroid carcinoma with intracranial iodine-131 uptake in brain
edema due to a frontal meningioma]. Nuklearmedizin 2000; 39(1): 38-39.

Schneider CA, Voth E, Moka D, Wagner R, Schicha H, Erdmann E, Baer FM.
[Dobutamine-induced changes in the myocardial blood flow in patients with coronary
heart diseases. A quantitative analysis using [15O] H2O positron emission tomography]. Dtsch Med Wochenschr 2000; 125(17): 512-516.

Schomäcker K, Schicha H. Use of myocardial imaging agents for tumour diagnosis-a
success story ? Eur J Nucl Med 2000; 27: 1845-1863.

Schwenk A, Eschner W, Kremer G, Ward LC. Assessment of intracellular water by
whole body bioelectrical impedance and total body potassium in HIV-positive patients. Clin Nutr 2000; 19(2): 109-113.

Sechtem U, Theissen P, Baer FM. [Magnetic resonance tomography in clinical
cardiology]. Z Kardiol 2000; 89(Suppl 1): 67-73.

Smolarz K, Malke G, Voth E, Scheidhauer K, Eckel HE, Jungehülsing M, Schicha H.
Hypothyroidism after therapy for larynx and pharynx carcinoma. Thyroid 2000; 10(5): 425-429.

Tate AR, Foxall PJ, Holmes E, Moka D, Spraul M, Nicholson JK, Lindon JC. Distinction
between normal and renal cell carcinoma kidney cortical biopsy samples using pattern
recognition of (1)H magic angle spinning (MAS) NMR spectra. NMR Biomed 2000;
13(2): 64-71.

Urbannek V, Schmidt M, Moka D, Hillger HW, Voth E, Wellner U, Schicha H. [Effect of
iodine application during radioiodine therapy in patients with impending therapy failure]. Nuklearmedizin 2000; 39(4): 108-112.

Nach oben scrollen